Catalyst Pharmaceuticals Inc (CPRX) reported stronger-than-expected financial results for the third quarter of fiscal 2025. The company achieved earnings per share (EPS) of $0.42, surpassing Wall Street's consensus estimate of $0.34 by $0.08. Revenues matched expectations at $0.1 billion.
This update provides insight into Catalyst's operational performance and financial health. The company focuses on developing and commercializing novel medicines for patients with rare diseases, including Lambert-Eaton myasthenic syndrome and Duchenne muscular dystrophy. With a market cap of $2,543.06 million and a price-to-earnings ratio of 12.19, Catalyst continues to position itself within the biotechnology sector.
Management will host an earnings conference call to discuss these results in detail and provide further commentary on business performance. Upcoming earnings are scheduled for May 4, 2026, with an EPS estimate of $0.357 and revenue expectations of $0.1 billion.
Investors are encouraged to review the full earnings release and listen to management's insights for a comprehensive understanding of the quarter's performance and future outlook.